Jazz Pharmaceuticals plc 4

Director Bruce C. Cozadd received an equity award of 1,605 restricted stock units of Jazz Pharmaceuticals plc on August 5, 2026.

On August 5, 2026, Bruce C. Cozadd, a non-employee director of Jazz Pharmaceuticals plc, received an award of 1,605 restricted stock units (RSUs) representing ordinary shares of the company under its 2007 Amended and Restated Non-Employee Directors Stock Award Plan, with each RSU convertible into one ordinary share upon vesting. The RSUs were granted at no cash cost to the reporting person as part of routine director compensation and will vest in full on July 23, 2027, subject to his continued service and other conditions. Following this equity award, Cozadd’s direct beneficial ownership increased to 362,287 ordinary shares (including RSUs), representing a modest incremental change in his overall stake and signaling continued alignment of director compensation with shareholder interests rather than an open-market purchase or sale.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

4

Source Type

fda

Accession

0001193210-26-000020

Alert Tier

5